Statins, obesity, and the microbiome: a potential mechanism for the pleiotropic effects of statin therapy

Kidney Int. 2021 Mar;99(3):531-533. doi: 10.1016/j.kint.2020.07.038. Epub 2020 Aug 19.

Authors

Martin Reichel¹, Felix Knauf²

Affiliations

¹ Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.
² Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany; Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, USA. Electronic address: Felix.Knauf@charite.de.

PMID: 32827500
DOI: 10.1016/j.kint.2020.07.038

No abstract available

Keywords: microbiome; obesity; statin.

Publication types

Comment

MeSH terms

Dysbiosis
Gastrointestinal Microbiome*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Microbiota*
Obesity / drug therapy
Prevalence

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors